Histamine H3 receptor agonists

Mini-Reviews in Medicinal Chemistry

Volumn 4, Issue 9, 2004, Pages 955-963

  De Esch, I J P ^a   Belzar, K J ^a  

^a De Novo Pharmaceuticals   (United Kingdom)

Author keywords

Activity; Affinity; Agonist; Efficacy; GPCR; H3; Histamine; Isoform

Indexed keywords

2 (2 PYRIDYL)ETHYLAMINE; 2 (2 THIAZOLYL)ETHYLAMINE; 2 METHYLHISTAMINE; 3 (1H IMIDAZOL 4 YLMETHYL)PYRROLIDINE; 4 METHYLHISTAMINE; ALPHA METHYLHISTAMINE; ALPHA,BETA DIMETHYLHISTAMINE; AMIDINE; AMTHAMINE; ANTIINFLAMMATORY AGENT; ANTINOCICEPTIVE AGENT; BETA CYCLOPROPYLHISTAMINE; BURIMAMIDE; HISTAMINE; HISTAMINE AGONIST; HISTAMINE DERIVATIVE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; IMETIT; IMPENTAMINE; IODOPROXYFAN; LIGAND; N METHYLHISTAMINE; N,N DIMETHYLHISTAMINE; PROPYLHISTAMINE; S [3 (4 IMIDAZOLYL)PROPYL]ISOTHIOUREA; TELE METHYLHISTAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VUF 4864; VUF 5202;

BINDING AFFINITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IN VIVO STUDY; NONHUMAN; PHARMACOLOGICAL BLOCKING; SHORT SURVEY; SPECIES DIFFERENCE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; METABOLISM; REVIEW; STEREOISOMERISM;

ANIMALS; HISTAMINE AGONISTS; HUMANS; LIGANDS; RECEPTORS, HISTAMINE H3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 6444230710     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557043403134     Document Type: Short Survey

References (42)

1. Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. Nature 1983, 302, 832-137.
2. Arrang, J. M.; Garbarg, M.; Schwartz, J.-C. Neuroscience 1987, 23, 149-157.
3. Leurs, R.; Blandina, P.; Tedford, C. ; Timmerman, H. TiPS 1998, 19, 177-183.
4. Chazot, P. L.; Hann, V. Overview. Current Opinion in Investigational Drugs 2001, 2(10), 1428-1431.
5. Lovenberg, T.W.; Rowland, B.L.; Wilson, S.J., Jiang, X.; Pyati, J.; Huvar, A.; Jackson, M.R.; Erlander, M.G. Mol. Pharmacol. 1999, 55, 1101-1107.
6. Lovenberg, T. W.; Pyati, J.; Chang, H.; Wilson, S. J.; Erlander, M. G. J. Pharmacol. Exp. Ther. 2000, 293, 771-778.
7. Tardivel-Lacombe, J.; Rouleau, A.; Heron, A.; Morisset, S.; Pillot, C.; Cochois, V.; Schwartz, J.C.; Arrang, J.M. Neuroreport 2000, 11, 755-759.
8. Drutel, G.; Peitsaro, N.; Karlstedt, K.; Wieland, K.; Smit, M.J.; Timmermann, H.; Panula, P.; Leurs, R. Mol. Pharmacol. 2001 59, 1-8.
9. Wellendorph, P.; Goodman, M. W.; Burstein, E. S.; Nash, N. R.; Brann, M. R.; Weiner, D. M. Neuropharmacol. 2002, 42, 929-940.
10. Hough, L.B. Mol. Pharmacol. 2001, 59, 415-419.
11. Wieland, K.; Bongers, G.; Yamamoto, Y.; Hashimoto, T.; Yamatodani, A.; Menge, W.M.B.P.; Timmermann, H.; Lovenberg, T.W.; Leurs, R. J. Pharmacol. Exp. Ther. 2001, 299, 908-914.
12. Lipp, R.; Stark, H.; Schunack, W. In Receptor Biochemistry and Methodology. Schwartz, J. C.; Haas, H. L. Eds. Wiley-Liss, Inc., New York, 1992; pp 57-72.
13. Uveges, A. J.; Kowal, D.; Zhang, Y.; Spangler, T. B.; Dunlop, J.; Semus, S.; Jones, P. G. J. Pharmacol. Exp. Ther. 2002, 301, 451-458.
14. Eriks, J. C.; Van der Goot, H.; Sterk, G. J.; Timmerman, H. J. Med. Chem. 1992, 35, 3239-3246.
15. Arrang, J.-M.; Garbarg, M.; Lancelot, J.C.; Lecomte, J.-M.; Pollard, H.; Robba, M.; Schunack, W.; Schwartz, J.-C. Nature 1987, 327, 117-123.
16. Lipp, R.; Arrang, J.-M.; Garbarg, M.; Luger, P.; Schwartz, J.-C.; Schunack, W. J. Med. Chem. 1992, 35, 4434-4441.
17. Lipp, R.; Arrang, J.-M.; Buschmann, J.; Garbarg, M.; Luger, P.; Schunack, W.; Schwartz, J.-C. In New perspectives in histamine research. Timmerman, H.; Van der Goot, H.; Eds., Bikhauser Verlag, Basel, 1991; pp 277-282.
18. Krause, M.; Rouleau, A.; Stark, H.; Luger, P.; Lipp, R.; Garbarg, M.; Schwartz, J.-C.; Schunack, W. J. Med. Chem. 1995 38, 4070-4079.
19. Rouleau, A.; Stark, H.; Schunack, W.; Schwartz, J.-C. J. Pharmacol. Exp. Ther. 2000, 295, 219-225.
20. Liu, C.; Ma, X-J.; Jiang, X.; Wilson, S. J.; Hofstra, C.; Blevitt, J.; Pyati, J.; Li, X.; Chai, W.; Carruthers, N.; Lovenberg, T. W. Mol. Pharmacol. 2001, 59, 420-426.
21. Van der Werf, J. G.; Bijloo, G. J.; Van der Vliet, A.; Bast, A.; Timmerman, H. Agents and Actions, 1987, 20, 239-243.
22. Schwartz, J.-C.; Arrang, J.-M.; Garbarg, M.; Schunack, W. In Innovative approaches in drug design. Harms, A. F., Ed.; Elsevier Science Publishers B. V., Amsterdam; 1986, pp 73-89.
23. Arrang, J.-M.; Schwartz, J.-C.; Schunack, W. Eur. J. Pharmacol. 1985, 117, 109-114.
24. 3 receptor. A target for new drugs. Leurs, R.; Timmerman, H., Eds.; Elsevier Science B. V.: Amsterdam.; 1998 ; pp 127-144.
25. De Esch, I. J. P.; Vollinga, R. C.; Goubitz, K.; Schenk, H.; Appelberg, U.; Hacksell, U.; Lemstra, S.; Zuiderveld, O. P.; Hoffmann, M.; Leurs, R.; Menge, W. M. P. B.; Timmerman, H. J. Med. Chem. 1999, 7, 1115-1122.
26. Shih, N-Y.; Lupo, Jr., A. T.; Aslanian, R.; Orlando, S.; Piwinski, J. J.; Green, M. J.; Ganguly, A. K.; Clark, M. A.; Tozzi, S.; Kreutner, W.; Hey, J. A. J. Med. Chem. 1995, 38, 1593-1599.
27. Shih, N.-Y.; Aslanian, R.; Lupo, Jr., A. T.; Duguma, L.; Orlando, S.; Piwinski, J. J.; Green, M. J.; Ganguly, A. K.; Clark, M.; Tozzi, S.; Kreutner, W.; Hey, J. A. Poster presented at New Perspectives in Histamine Research. Riding Mountain National Park, Manitoba, Canada, 1994.
28. Hey, J. A.; Aslanian, R.; Bolser, D. C.; Chapman, R. W.; Egan, R. W.; Rizzo, C. A.; Shih, N. -Y.; Fernandez, X.; McLeod, R. L.; West, R.; Kreutner, W. Arzneim.-Porsch./Drug Res. 1998, 48 9), 881-888.
29. Van der Goot, H.; Schepers, M. J. P.; Sterk, G. J.; Timmerman, H. Eur. J. Med Chem. 1992, 27, 511-517.
30. Howson, W.; Parson, M. E.; Raval, P.; Swayne, G. T. G. Bioorg. Med. Chem. Lett. 1992, 2, 77-78.
31. Garbarg, M.; Arrang, J.-M.; Rouleau, A.; Ligneau, X.; Tuong, M. D. T.; Schwartz, J.-C.; Ganellin, C. R. J. Pharmacol. Exp. Ther. 1992, 263, 304-310.
32. Ganellin, C. R.; Bangandersen, B.; Khalaf, Y. S.; Tertiuk, W.; Arrang, J.-M. Garbarg, M.; Ligneau, X.; Rouleau, A.; Schwartz, J.-C. Bioorg. Med. Chem. Lett. 1992, 2, 1231-1234.
33. 3 receptor; Synthesis, structure activity relationships and molecular pharmacology. Vrije Universiteit, Amsterdam, The Netherlands, 1996.
34. Vollinga, R. C.; De Koning, J. P.; Jansen, F. P.; Leurs, R.; Menge, W. M. P. B.; Timmerman, H. J. Med. Chem. 1994, 37 332-333.
35. De Esch, I. J. P.; Timmerman, H.; Menge, W. M. P. B.; Nederkoorn, P. H. J. Archive Pharmazie 2000, 333, 254-261.
36. Harusawa, S.; Imazu, T.; Takashima, S.; Araki, L.; Ohishi, H.; Kurihara, T.; Yamamoto, Y.; Yamatodani, A. Tetrahedron Lett. 1999, 40, 2561-2564.
37. Kovalainen, J. T.; Christiaans, J. A. M.; Poso, A.; Vepsalainen, J.; Laatikainen, R.; Gynther, J. Tetrahedron Lett. 1999, 40, 12, 2425-2428.
38. Leurs, R.; Kathman, M.; Vollinga, R. C.; Menge, W. M.; Schlicker, E.; Timmerman, H. J. Pharmacol. Exp. Ther. 1996, 276, 1009-1015.
39. Ligneau, X.; Garbarg, M.; Vizuete, M. L.; Purand, K.; Stark, H.; Schunack, W.; Schwartz, J.-C. J. Pharmacol. Exp. Ther. 1994 271, 452-459.
40. Schlicker, E.; Kathmann, M.; Bitschnau, H.; Marr, I.; Reidemeister, S.; Stark, H.; Schunack, W. Naunyn-Schmiedeberg's Arch. Pharmacol. 1996, 353, 482-488.
41. Gether, U.; Kobilka, K.B. J. Biol. Chem. 1998, 273, 17979-17982.
42. Beck-Sickinger, A. G. Drug Discov. Today 1996, 1(12), 502-513.